ALS Biotech Firm Amylyx Pharmaceuticals Launches Nasdaq IPO

Clinical-stage biopharmaceutical company Amylyx Pharmaceuticals is looking to go public on the Nasdaq Global Select Market. The firm announced today the launch of its initial public offering of 8.75 million common shares.

The biotech firm is targeting the share price between US$18.00 and US$20.00 per share, which puts target proceeds from the offering at US$175 million on the high end of the range.

The shares are expected to trade on the Nasdaq big board under the symbol “AMLX”. The underwriters also have a 30-day over-allotment option to purchase additional 1.3 million shares.

The pharmaceutical firm has two drug candidates in its pipeline currently in clinical trials to treat amyotrophic lateral sclerosis (ALS) and one for Alzheimer’s disease.


Information for this briefing was found via Edgar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News